Canopy Growth Corporation (CGC) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Canopy Growth (CGC) by buying shares or fractional shares at any major US broker, through a cannabis or alternative-agriculture ETF that holds it, or as one holding in a thematic basket. Canopy sells adult-use and medical cannabis in Canada, ships medical cannabis internationally, and owns the Storz & Bickel vaporizer brand, while a separate vehicle called Canopy USA holds American cannabis assets to activate if federal law allows. The single biggest thing to understand is that this is a small, still-unprofitable turnaround: the business has returned to growth and narrowed its losses, but it remains loss-making, has diluted shareholders heavily, and depends on cannabis regulation it does not control.
CGC stock price
As of 2026-07-14, Canopy Growth Corporation (CGC) last closed at $0.9572, down 18.2% over the past year. Over the past 52 weeks it has traded between $0.8570 and $1.92.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Canopy Growth Corporation's investor relations page. Walnut is informational, not investment advice.
What does Canopy Growth Corporation (CGC) do?
Canopy Growth Corporation is one of Canada's largest cannabis companies, based in Smiths Falls, Ontario. It sells recreational (adult-use) and medical cannabis in Canada, exports medical cannabis to international markets in Europe and Australia, and owns Storz & Bickel, a maker of premium vaporizer devices. Its revenue comes mainly from selling cannabis flower, pre-rolls, vapes, edibles, and beverages under brands like Tweed and Doja, plus device sales. In fiscal 2026 the company completed its acquisition of MTL Cannabis, a move it says makes it Canada's leading medical-cannabis provider by revenue, and reported that its core cannabis business returned to growth after years of contraction.
Canopy became a household name in the cannabis boom of the late 2010s, drawing a multibillion-dollar investment from Constellation Brands, but it later wrote down large acquisitions like BioSteel and Wana and burned through cash. The mid-2026 picture is a company in the middle of a hard reset: fiscal 2026 revenue rose modestly, driven by double-digit growth in Canadian adult-use, Canadian medical, and international cannabis, while its net loss from continuing operations narrowed sharply versus the prior year. A January 2026 recapitalization left it with a net-cash position for the first time in a while. Its US ambitions run through Canopy USA, a separate holding structure that owns stakes in Acreage, Wana, and Jetty and is designed to consolidate those plant-touching American assets only when US federal law permits.
What's driving Canopy Growth Corporation (CGC)?
1. Core cannabis business back to growth
After years of shrinking revenue, Canopy reported that fiscal 2026 brought its cannabis business back to top-line growth, with double-digit gains in Canadian adult-use, Canadian medical, and international cannabis. Quarterly net revenue rose year over year. Returning to growth is the first requirement for any turnaround, and it suggests the product portfolio and distribution are stabilizing after heavy restructuring.
2. MTL Cannabis and medical leadership
Canopy completed its acquisition of MTL Cannabis in fiscal 2026, which it says positions the company as Canada's leading medical-cannabis provider by revenue. Medical cannabis tends to carry steadier demand and better margins than the crowded, price-competitive adult-use market. Building scale in medical, alongside international medical exports to Europe and Australia, is central to Canopy's plan to reach sustainable profitability.
3. Balance-sheet reset and lower losses
A recapitalization completed in January 2026 left Canopy with a net-cash position, and its fiscal 2026 net loss from continuing operations came in roughly half the prior year's. Cutting debt and burn buys time for the turnaround to work. The company has spent years reducing its cost base and shedding non-core assets, and a cleaner balance sheet reduces the near-term risk of forced, highly dilutive financing.
4. US optionality through Canopy USA
Canopy USA is a separate holding structure that owns interests in American cannabis assets, including Acreage, Wana edibles, and Jetty vapes, plus retail and flower brands. It is designed to consolidate those plant-touching businesses when US federal law allows. That gives Canopy a call option on the large US market, potentially the biggest long-term prize, but the value only unlocks if and when federal cannabis reform actually happens.
What are the risks to Canopy Growth Corporation (CGC)?
The central risk is that Canopy is still unprofitable in a brutally competitive industry. Canadian adult-use cannabis suffers from oversupply and price compression, which squeezes margins even as volumes grow. The company has a long history of large writedowns (BioSteel, Wana, and others) and heavy share dilution, so existing shareholders have repeatedly been diluted to fund losses. Its US upside through Canopy USA depends on federal reform that has been promised for years without arriving, and remains outside the company's control. Canopy also restated prior-period financials for non-cash technical errors tied to certain US-dollar share-settled warrants. As a small-cap cannabis stock, CGC is highly volatile and sensitive to sentiment, financing conditions, and regulatory headlines, with no guarantee the turnaround reaches sustained profitability.
How is Canopy Growth Corporation (CGC) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Canopy Growth Corporation's investor relations page or your broker.
- Revenue trend (FY2026): Modest annual growth (roughly mid-single-digit percent), the first sustained return to growth after years of contraction
- Growth drivers: Double-digit gains in Canadian adult-use, Canadian medical, and international cannabis; device sales (Storz & Bickel) were softer
- Profitability: Still net-loss-making, but fiscal 2026 net loss from continuing operations narrowed roughly by half versus the prior year
- Balance sheet: Shifted to a net-cash position after a January 2026 recapitalization, reducing near-term financing risk
- Share count / dilution: History of heavy dilution to fund losses and acquisitions; a key thing to watch for existing holders
- Valuation basis: No meaningful P/E because the company is unprofitable; valued on revenue, cash, and turnaround potential rather than earnings
These figures are qualitative and tied to the asOf date; verify live numbers before acting. Because Canopy is unprofitable, standard earnings multiples do not apply, and the stock trades on revenue trajectory, cash runway, and expectations for cannabis reform rather than on profits. Reported financials are also in Canadian dollars, so US-dollar figures depend on exchange rates. Treat any single quarter with caution: cannabis results swing on pricing, one-time charges, and restructuring.
Who competes with Canopy Growth Corporation (CGC)?
Canadian cannabis producers
Tilray Brands, Aurora Cannabis, Organigram, and Cronos Group are the other large licensed producers competing in the same crowded Canadian adult-use and medical markets. Like Canopy, several have expanded internationally and struggled with oversupply and price compression at home. Tilray in particular has diversified into beverages and international medical to reduce its reliance on Canadian recreational cannabis.
US multi-state operators
Curaleaf, Green Thumb Industries, Cresco Labs, and Trulieve are vertically integrated US operators that already sell plant-touching cannabis in state-legal markets. They are the businesses Canopy hopes to compete with through Canopy USA once federal law permits consolidation, and several are profitable or cash-generative in ways Canopy is not yet, giving them a head start in the largest market.
Adjacent and alternative exposure
Broader beverage and consumer companies (Constellation Brands, a longtime Canopy investor, among them) and cannabis-focused ETFs offer indirect exposure to the theme. ETFs spread single-stock risk across many cannabis names, while device and ancillary players compete with Canopy's Storz & Bickel vaporizer business rather than in cultivation.
How to invest in Canopy Growth Corporation (CGC)
There are three common ways to get CGC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CGC sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where CGC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Canopy Growth Corporation (CGC)
Canopy Growth is a speculative cannabis turnaround: it has returned its core business to growth, cut its losses roughly in half, and shifted to a net-cash balance sheet, but it is still losing money and its US upside hinges on federal reform. It fits risk-tolerant investors, not those seeking stability.
Build a basket around CGC with Walnut
Use Canopy Growth Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CGC a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a genuine turnaround: core cannabis revenue back to growth, losses roughly halved, a net-cash balance sheet, and US optionality through Canopy USA. The bear case is that Canopy is still unprofitable, has diluted shareholders heavily, competes in an oversupplied market, and depends on US reform that keeps being delayed. It is a speculative, high-volatility holding.
What does Canopy Growth actually do?
+
Canopy is a Canadian cannabis company. It grows and sells adult-use and medical cannabis in Canada under brands like Tweed and Doja, exports medical cannabis to international markets such as Europe and Australia, and owns Storz & Bickel, a maker of premium vaporizer devices. It also holds US cannabis assets through a separate structure called Canopy USA, meant to activate when federal law allows.
Is Canopy Growth profitable?
+
No, not yet. Canopy remains net-loss-making, though in fiscal 2026 it narrowed its net loss from continuing operations to roughly half the prior year's level and returned its core cannabis business to revenue growth. A January 2026 recapitalization also left it with a net-cash position. Reaching sustained profitability is the central open question for the stock, and there is no guarantee it gets there.
What is Canopy USA?
+
Canopy USA is a separate holding structure Canopy created to own American cannabis assets, including interests in Acreage, the Wana edibles brand, and Jetty vapes, plus flower and retail brands. Because US cannabis remains federally illegal, plant-touching assets are held in this vehicle and are designed to be consolidated into Canopy only if and when federal law permits. It gives Canopy a call option on the large US market.
Why has Canopy Growth stock fallen so much over the years?
+
After the late-2010s cannabis boom, Canopy overexpanded, made large acquisitions it later wrote down (such as BioSteel and Wana), and burned through cash while Canadian adult-use prices collapsed under oversupply. To fund those losses it issued many new shares, diluting existing holders. The combination of writedowns, ongoing losses, and heavy dilution drove the long decline the recent turnaround is trying to reverse.
Does Canopy Growth pay a dividend?
+
No. Canopy Growth does not pay a dividend. As an unprofitable company still investing in a turnaround and conserving cash, it directs any available capital toward operations and its business rather than shareholder payouts. Investors buy CGC for potential price appreciation from a successful turnaround and possible US market entry, not for income.
How does US cannabis reform affect Canopy?
+
US federal cannabis remains illegal, which is why Canopy holds its American assets in the separate Canopy USA structure rather than on its own books. Meaningful federal reform, such as rescheduling or legalization, could let Canopy consolidate those plant-touching businesses and compete directly in the large US market. That upside is real but uncertain, since reform has been anticipated for years without arriving.
How can I get exposure to Canopy Growth through an ETF?
+
CGC appears in several cannabis-focused and alternative-agriculture ETFs, where it sits alongside other producers like Tilray and US multi-state operators. ETF exposure spreads single-stock risk across many volatile cannabis names but dilutes how much any Canopy move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to Canopy specifically.
What are the main risks of investing in CGC?
+
The biggest risks are continued unprofitability, further share dilution to fund losses, and a Canadian market plagued by oversupply and price compression. Its US upside depends on federal reform outside its control, its history includes large writedowns and restated financials, and as a small-cap cannabis stock it is highly volatile and sentiment-driven. There is no guarantee the turnaround reaches sustained profitability.
Is Canopy Growth being delisted?
+
As of mid-2026 Canopy Growth continues to trade on the Nasdaq under the ticker CGC and on the Toronto Stock Exchange. In the past it has had to manage exchange listing requirements, including maintaining a minimum share price, which is one reason it previously carried out a reverse stock split. Listing status can change, so always confirm current trading status before investing.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Canopy Growth Corporation's investor relations page or your broker before making investment decisions.